Shedding of several RTKs, especially AXL, has been shown in patients with breast cancer and melanoma, and their circulating levels exhibited variable reduction in patients with melanoma after treatment with a combination of the MEK inhibitor trametinib and the BRAF inhibitor dabrafenib. This evidence concerns the gene MAP2K7 and melanoma.